


The listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) ~~The use of a~~ A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, ~~in the preparation of a composition for inhibition of HSP90 activity:~~



wherein

R_1 is a group of formula (IA):



wherein in any compatible combination

Ar^1 is an optionally substituted aryl or heteroaryl radical,

Alk^1 and Alk^2 are optionally substituted divalent C_1-C_6 alkylene or C_2-C_6 alkenylene radicals,

p , r and s are independently 0 or 1,

Z is $-O-$, $-S-$, $-(C=O)-$, $-(C=S)-$, $-SO_2-$, $-C(=O)O-$, $-C(=O)NR^A-$, $-C(=S)NR^A-$, $-SO_2NR^A-$, $-NR^AC(=O)-$, $-NR^ASO_2-$ or $-NR^A-$ wherein R^A is hydrogen or C_1-C_6 alkyl, and

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

R_2 is (i) a group of formula (IA) as defined in relation to R_1 ;

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is

optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula $-(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)-\text{Q}$ wherein Q, Alk¹, Alk², Z, p, r and s are as defined above in relation to group (IA); and

R₃ is hydrogen, or methyl, ethyl, n- or iso-propyl any of which being optionally substituted by hydroxy;


X is $-\text{OR}_4$ or $-\text{NR}_4\text{R}_5$ wherein R₄ and R₅ independently represent hydrogen or optionally substituted C₁-C₆ alkyl, or R₄ and R₅ taken together with the nitrogen to which they are attached form an optionally substituted nitrogen-containing ring having 5-8 ring atoms.

2. (Currently Amended) The ~~use~~-compound as claimed in claim 1 wherein in the compound of formula (I), R₁ has formula (IB):



wherein R₆ is chloro, bromo, C₁-C₆ alkyl, or cyano.

3. (Currently Amended) The ~~use~~-compound as claimed in claim 1 wherein in the compound of formula (I) R₁ has formula (IC):



wherein Alk¹, Alk², p, r, s, Z and Q are as defined in claim 1 in relation to formula (IA), and R represents one or more optional substituents.

4. (Currently Amended) The use-compound as claimed in claim 2 wherein R is -OH in the 4- position of the phenyl ring and the -(Alk¹)_p-(Z)_r-(Alk²)_s-Q substituent is in the 5- position of the phenyl ring.
5. (Currently Amended) The use-compound as claimed in claim 4 wherein r is 0, and Q is hydrogen or optionally substituted phenyl.
6. (Currently Amended) The use-compound as claimed in claim 5 wherein s is 0, p is 1 and Alk¹ is a nonsubstituted divalent C₁-C₆ alkylene or C₂-C₆ alkenylene radical.
7. (Currently Amended) The use-compound as claimed in claim 5 wherein Alk¹ is -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, or -CH=CH-.
8. (Currently Amended) The use-compound as claimed in claim 4 wherein p, r and s are each 0.
9. (Currently Amended) The use-compound as claimed in ~~any of the preceding claims~~ claim 1 wherein R₂ is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.
10. (Currently Amended) The use-compound as claimed in ~~any of claims 1 to 8-claim 1~~ wherein R₂ is optionally substituted phenyl.
- 11 (Currently Amended) The use-compound as claimed in ~~any of claims 1 to 8-claim 1~~ wherein R₂ is phenyl substituted in the 4 position by (i) C₁-C₆ alkoxy such as methoxy or ethoxy, fluoro, chloro, bromo, morpholinomethyl, piperazino, N-methylpiperazino, or piperidino, (ii) optionally substituted C₁-C₆ alkyl, eg optionally substituted methyl, ethyl, n-propyl or iso-propyl (iii) optionally substituted morpholino C₁-C₆ alkyl-, thiomorpholino C₁-C₆ alkyl-, piperazino C₁-C₆ alkyl-, methyl piperazino C₁-C₆ alkyl-, or diethylamino (iv) -NH₂, -NHR^A, -NR^AR^B, -NHCOR^A, -NHCOOR^A, NR^BCOOR^A, -NHSO₂0R^A, -NR^BSO₂OR^A,

-NHCONH₂, -NR^ACONH₂, NHCONHR^B, -NR^ACONHR^B, -NHCONR^AR^B, or -NR^ACONR^AR^B wherein R^A and R^B are independently a (C₁-C₆) alkyl group or (v) optionally substituted piperadino, piperazino, morpholino or thiomorpholino.

12. (Currently Amended) The ~~use compound~~ as claimed in ~~any of claims 1 to 8-claim 1~~ wherein R₂ is a carboxamide radical of formula -CONR^B(Alk)_nR^A wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1 ,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

13. (Currently Amended) The ~~use-compound~~ as claimed claim 12 wherein

Alk is an optionally substituted -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH=CH-, or -CH₂CCCH₂- radical.

n is 0 or 1,

R^B is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^A is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or R^A and R^B taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

14. (Currently Amended) The ~~use-compound~~ as claimed in claim 12 wherein n is 0, R^B is hydrogen and R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

15. (Currently Amended) The ~~use-compound~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R₃ is hydrogen.

16. (Currently Amended) The ~~use-compound~~ as claimed in ~~any of claims 1 to 14~~ claim 1 wherein R₃ is other than hydrogen and the stereochemical configuration at the carbon centre to which it is attached is that of a D amino acid.

17. (Currently Amended) The ~~use-compound~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein X is -OR₄ or -NHR₄ wherein R₄ is C₁-C₆ alkyl, optionally substituted by hydroxy, or a primary- secondary, tertiary- or cyclic-amino group

18. (Currently Amended) The ~~use-compound~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein X is -NR₄R₅ wherein R₄ and R₅ taken together with the nitrogen to which they are attached form a morpholino, piperidinyl or piperazinyl ring, the latter being optionally substituted by C₁-C₆ alkyl on the second nitrogen.

19. (Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in ~~any of claims 1 to 15~~ claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.




20. (Currently Amended) The ~~use as claimed in any of claims 1 to 18 or a method as claimed claim 16~~ claim 19 for immunosuppression or the treatment of cancer, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-






related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.





21. (Canceled)


22. (Canceled)

23. (Currently Amended) A compound ~~whose structure is set forth in any of the Examples herein;~~









or a salt, solvate or hydrate thereof.

24. (Currently Amended) A pharmaceutical or veterinary composition comprising a compound as defined in ~~claim 22 or claim 23~~ 1, together with a pharmaceutically or veterinarilly acceptable carrier.